We thank Monnier et al. (1) for both their interest in our trial (2) and their thoughtful comments. We appreciate their suggestion regarding a possible relationship between exogenous insulin dosage and the observed levels of urinary 8-iso-prostaglandin F2α, which we plan to address in the future in a more detailed analysis of this and other markers of cardiovascular risk. The upcoming analyses are intended to explore whether changes seen in these measurements are related to the treatment regimens themselves, to changes of glycemic variability attained, or to other on-treatment effects such as change of weight. We also thank Monnier et al. for pointing out our inadvertent mistake in the assignment of units associated with 8-iso-prostaglandin F2α values, which should be in pg/mL.
Duality of Interest. K.D.O. reports having received grant support from Sanofi. I.B.H. reports receiving honoraria for consulting from Roche, Abbott Diabetes Care, and Becton Dickinson and receiving grants from Sanofi and Intarcia. M.C.R. reports having received grant support from Sanofi, AstraZeneca, Eli Lilly, and Novo Nordisk; honoraria for speaking from Sanofi; and honoraria for consulting from Sanofi, AstraZeneca, Eli Lilly, Elcelyx, Valeritas, and Biodol. J.L.P. reports receiving honoraria for consulting from Sanofi and receiving research grant support from Sanofi, Bristol-Myers Squibb/AstraZeneca, Eli Lilly, and Bayer. No other potential conflicts of interest relevant to this article were reported.
- © 2016 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.